KreaMedica Blog

Subscribe to learn about new product features, the latest in technology, solutions, and updates.

All Blog Posts

Website 2

Going the Distance: A conversation with KreaMedica founder Karl-Rudolf (Rudi) Erlemann

[short_description_excerpt]

Most marathon runners know the wall, the point late in a race when the body runs out of fuel and the finish still feels a

Website

A Spotlight on a KreaMedica Expert: Dominic Poulin

[short_description_excerpt]

Before any new drug can be tried in people, regulators need evidence that it’s reasonably safe. Most of that evidence comes from preclinical safety studies,

dom

Designing a Toxicology Program Around Your First Clinical Trial

[short_description_excerpt]

A toxicology program has one job: to show that a drug is safe enough for a specific use in specific people. That makes the first

Blog post Carlos 1

Which studies actually increase the value of a biotech asset?

[short_description_excerpt]

A biotech company can spend years and millions of dollars generating solid data and still find that its asset is no more compelling to a

NAMs

NAMs Are Not a Shortcut — They Are a Better Decision Tool

[short_description_excerpt]

New Approach Methodologies, or NAMs, are no longer a niche topic in drug development. They are increasingly part of how teams think about human relevance,

2

What Drug Development Is Missing: A General Contractor

[short_description_excerpt]

Drug programs fail more often than they succeed. When one falters, people usually assume it was because the science didn’t pan out. Sometimes, that’s the

iStock 1321462048

Five Trends Defining the Next Decade of Drug Development

[short_description_excerpt]

A drug discovered by an algorithm. An organ-on-a-chip used to test pharmacology. An injection taken twice a year that cuts cholesterol in half. These are

iStock 1397430023

Beyond the Science: Fundraising lessons for first-time biotech CEOs

[short_description_excerpt]

This January, thousands of healthcare leaders from around the world gathered in San Francisco for the 44th Annual J.P. Morgan Healthcare Conference. The city buzzed

Canada Global Biotech Powerhouse

Competing for the Future of Biotech: Positioning Canada to emerge as a global leader in R&D investment

[short_description_excerpt]

Published in BIOTECanada Insights Magazine WHEN A BIOTECH STARTUP gears for its next major trial, the focus is often on the science and funding—but geography

Screenshot 2025 11 03 134243

The Three Factors That Predict Consultant Success

[short_description_excerpt]

A promising biotech program hits a critical regulatory decision point. The team hires a highly credentialed consultant with decades of pharmaceutical executive experience. Three months

iStock 1209892070 scaled

Rewriting the Rules of Drug Development with AI

[short_description_excerpt]

Drug development is one of the most challenging endeavors in science. The journey from laboratory to pharmacy typically takes over a decade, costs around $1-3

investment blog post linkedin 2 e1755712519331

A Spotlight on a KreaMedica Investment: Vincere Biosciences

[short_description_excerpt]

Inside Vincere’s quest to transform treatments against neurodegeneration using artificial intelligence What happens when a software engineer marries a neuroscientist? In Andy Lee and Dr.

AirRnD blog post linkedin KREACONNECT2

KreaConnect: the Airbnb of Biotech Consulting

[short_description_excerpt]

It wasn’t that long ago when booking travel accommodations meant settling between two often unsatisfying options: pricey chain hotels with cookie-cutter service, or uncertain stays

iStock 915093200

The World Next Door: Sizing up the relative advantages of conducting R&D in Australia and Canada

[short_description_excerpt]

Australia has become a popular location for US biopharma companies to conduct R&D operations, thanks to the tax offsets available under its well-known Research and

Planning for Success Four Preclinical Drug Development Pitfalls to Watch For

Planning for Success: Four Preclinical Drug Development Pitfalls to Watch For

[short_description_excerpt]

More than 90% of drug candidates never make it to market. Many potential treatments fail not because the science is flawed but due to poor

3 ways the right consultant drives your drugs success scaled

How The Right Biotech Consultant Drives Your Drug’s Developmental Success

[short_description_excerpt]

Picture this scenario: You’ve transitioned from an investigator-driven IND to a commercial submission, only to discover your CMC data falls short of requirements. Suddenly, you’re

Navigating FDA changes A guide for drug developers

Navigating FDA Changes: A Guide For Drug Developers

[short_description_excerpt]

The biotech industry is experiencing significant shifts following President Trump’s return to office. If you’re a drug developer watching these developments unfold, you might be

cell therapy scaled

A Basic Overview of Cell Therapy

[short_description_excerpt]

Cell therapy is an advanced approach for treating rare or complex disorders. Innovations in this field allow us to treat patients more effectively with better

Clinical Development Program United States

Bringing a Clinical Development Program to the United States

[short_description_excerpt]

The United States is one of the largest and most influential markets for pharmaceuticals, making it an important destination for many global clinical development programs.

pre ind meeting tips scaled

Conducting a Successful Pre-IND Meeting

[short_description_excerpt]

Your drug development project’s acceptance and success depend heavily on your IND application. Getting it right the first time is critical. Holding a pre-IND meeting

psychadelic research

Overcoming Hurdles in Psychedelic Treatment Development: Navigating the Regulatory Maze

[short_description_excerpt]

Hippie Counter-Culture or Wonder Drugs? In recent years, the resurgence of interest in psychedelic substances as potential therapeutic tools has captured both scientific curiosity and

t cell

Non-Clinical Development Strategies for T-cell Engaging Molecules

[short_description_excerpt]

Innovative approaches in developing T-cell-engaging molecules are shifting the idea of what’s possible in our medical landscape. To see these transformative immunotherapies change lives, developers